Professionals 247 Users Online

Recombinant Cell Culture Supplements Market

Effective use of recombinant cell culture supplements in stem cell therapy based cancer research application will drive the global market over forecast duration

Recombinant Cell Culture Supplements Market Segmented By Products - Recombinant Growth Factors | Recombinant Insulin | Recombinant Albumin | Recombinant Transferrin | Recombinant Trypsin | Recombinant Aprotinin | Recombinant Lysozyme

Recombinant Cell Culture Supplements Market Outlook (2023-2033)

Worldwide revenue from the recombinant cell culture supplements market reached a valuation of around US$ 495.5 Mn at the end of 2022, with the global market forecasted to surge ahead at a CAGR of 6.0% to reach a valuation of US$ 947.7 Mn by the end of 2033.

The global market for recombinant cell culture supplements recorded a historic CAGR of 5.8% in the last 8 years from 2014 to 2022. Overall, recombinant cell culture supplements sales accounted for 16.5% of the US$ 3.0 Bn global cell culture media market in 2022.

The development of bioprocesses, gene therapy, and stem cell research are the main applications using recombinant cell culture supplements. Stem cells are supplied with these nutrients and growth substances to encourage differentiation into particular cell types or to expand their culture. Cell culture supplements are growth media additives required for a cell's healthy reproduction or expansion. Mammalian cells, for example, need extra substances in addition to the basal medium. These consist of proteins, carbohydrates, vitamins, and amino acids.

Since the past few years, the need for recombinant cell culture supplements has increased exponentially. Additionally, the growing interest in oncology and stem cell research has opened doors for manufacturers. Recombinant products have benefits including mass manufacture of growth factors and supplements at lower manufacturing costs. The pharmaceutical industry's approach to creating medicines and products that support research has been changed by recombinant DNA technology.

The introduction of advanced therapeutics and biopharmaceuticals, or biologics, has led to a major expansion recombinant cell culture supplements market. During the projection period, demand is anticipated to increase significantly due to drug discovery activities. The demand for biologics and animal-free products is predicted to change the biopharmaceutical business in the future.

The increased incidence of cancer is another major factor boosting the recombinant cell culture supplements market. According to the WHO, cancer is the second most common cause of death. The burden of chronic diseases is rapidly increasing on a global scale. Accordingly, it is anticipated that the market for recombinant cell culture supplements would expand as a result of growing demand for treating chronic diseases in a specific way, which has increased expenditure on R&D projects on the development of effective cell cultures.

Stem cell research continues to grow and develop, and stem cell therapies are becoming more and more popular with time. To facilitate the clinical development of cellular therapies, recombinant cell culture supplements are becoming increasingly popular, as a result, boosting the market.

Recombinant Cell Culture Supplements Market Size (2022)

US$ 495.5 Mn

Projected Market Value (2033)

US$ 947.7 Mn

Global Market Growth Rate (2023-2033)

6.0% CAGR

Market Share of Top 5 Countries

60.1%

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Why is the Global Recombinant Cell Culture Supplements Market Growing?

Demand for the Animal Free Recombinant Cell Culture Supplements”

The global market for recombinant cell culture supplements is anticipated to develop as a result of the extensive use of animal free recombinant cell culture supplements in various research purposes. Animal Free recombinant cell culture supplements remain contaminant-free since they are devoid of animal components like as serum, endotoxins, and endogenous mammalian contamination. As consumer demand for these animal-free products rises, manufacturers are concentrating on delivering animal-free recombinant cell culture supplements on the market.

  • For instance, numerous manufacturers offer growth factors free of animal products in their product line-up. Animal-free growth factors are produced by companies like Sigma-Aldrich, Laurus Bio, BioBetter and Gemini Bio Products.

“Increasing Demand for Growth Factor in Regenerative Medicine”

Growth factors have a vital role in the regeneration of numerous tissue. There is a high demand for recombinant growth factors for periodontal problems and diabetic neuropathic ulcers. Examples include bone morphogenetic proteins and platelet-derived growth factor. The need for recombinant cell culture supplements is expected to increase due to increasing prospects for gene therapy and regenerative medicine research.

“Increase in Life Science Research Funding”

The expansion of several projects conducted and the employment of new staff are facilitated by funding for life science research and investments in the sectors of growth factors, cytokines, and biologics. Governments, commercial organizations, and private funding are some of the sources of R&D expenditures.

  • The National Institutes of Health (NIH) in the U.S. awarded research grants totalling more than $42.9 billion in 2021.

In the upcoming years, the market for recombinant cell culture supplements is projected to grow globally, particularly in nations like China and India, due to increased investment in R&D in the biopharmaceutical industry.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Can Demand for Recombinant Cell Culture Supplements Be Affected in Any Way?

Restricting Recombinant Cell Culture Supplements Demand Due to High Cost”

Researchers in the field of life sciences have increasingly complex requirements, which has resulted in the development of new, expensive products. Many consumers do not like to invest in such expensive products, especially for research groups with limited resources and financing, because to the uncertainty in the findings expected from complex experiments. A constraint for most laboratories is the high cost of several recombinant cell culture supplements. Most major suppliers of research products have catalogues, but custom research products and services are typically several times more expensive.

“Lack of Skilled Professionals”

Unfortunately, there is a lack of qualified personnel working in research and development. The shortage of qualified professionals is mostly caused by low pay scales, complex duties, and inadequate laboratory training. Skilled professionals are needed to manage research and development based on cell culture, growth factors, and biologics.

As a result, the global market for recombinant cell culture supplements may not increase as expected due to a lack of skilled professionals and a lack of equipment and other accessories associated with research laboratories.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Country-wise Insights

Why is the U.S. a Huge Market for Recombinant Cell Culture Supplements Manufacturers?

“Ongoing Projects and Government Support”

The U.S. accounted for around the largest share of the North American market in 2022, contributing nearly US$ 172.4 Mn in terms of revenue, and a similar trend is expected over the forecast period.

The U.S. market is being driven by an increase in research and development expenditure. Top institutions like the National Cancer Institute (NCI) and others invest in significant research projects to enable and promote research on particular challenges related to cancer. The National Cancer Institute had previously made investments in initiatives like Cancer Moonshot. Recombinant cell culture supplements will be in great demand as a result of government and academic efforts, as well as ongoing research in the field of oncology.

What is the Scenario for Recombinant Cell Culture Supplements Market in Germany?

“Presence of Major Players”

Germany held 27.2% share of the European market in 2022.

Germany will have higher returns due to the presence of certain major players including OLS OMNI Life Science GmbH, Co. Kg, Cytiva Europe GmbH, and Becton, Dickinson and Company. Additionally, the nation's expanding contract research manufacturing and R&D activities will lead to a significant increase in demand for recombinant cell culture supplements. In therapeutic areas like cancer, German companies and research institutions also have a robust pipeline.

How is China Emerging as a Prominent Market for Recombinant Cell Culture Supplements?

“Increasing Drug Discovery and Research Activities”

China held the largest market share of 50.0% of the East Asia market in 2022.

Techniques for mammalian cell culturing have improved throughout time. It can be claimed that China is at the forefront of technology adoption. The discovering new drugs has made substantial use of cell culture techniques, such as cell-based tests. Recombinant cell culture supplements are being more widely used as a result of increasing drug discovery and research activities in China. Also, one of the world's largest biopharmaceutical sectors is found in China.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Category-wise Insights

Which Product is Largely the Focus in the Global Market?

“Extensive Application in Cancer Research”

The recombinant growth factors segment dominated the market generating a revenue of US$ 241.8 Mn in 2022.

Recombinant cell culture supplements are crucial for cancer research. Recombinant growth factors and oncogenes are related, which has improved the understanding of how cancer develops and has given new chemotherapeutic targets. Cancer research and diagnosis heavily rely on recombinant growth factors like VEGF, epidermal growth factors, and platelet-derived growth factors. They are the segment leader due to their significant use in cancer research.

Which Application Segment Displays Greater Adoption of Recombinant Cell Culture Supplements?

“Increasing Application of Stem Cell Therapy in Treating Variety of Disorders”

Stem cell therapy held the largest market share under the application segment globally in 2022. The segment contributed revenue of US$ 161.0 Mn in 2022.

Due to the escalating research carried out over the past decades, stem cell therapy is steadily moving closer to becoming a reality. The potential uses for stem cells are expanding with each research study. With claims of clinical success in treating a variety of disorders, including macular degeneration and neurological diseases, stem cell research is currently making great strides. With countless potential applications for treating diseases with patients' own cells, as a result, stem cell therapy is the dominating the segment.

Which Source of Recombinant Cell Culture Supplements is Driving the Market?

Animal source of supplements have driven the global market by achieving a valuation of US$ 286.7 Mn by the end of 2022.

Animal-based supplements are more frequently used because of their essential importance as a source of proliferative and adhesion factors for the culture of cells in the media. The permeability of cell membranes is also regulated by animal-based supplements, which also serve as a channel for lipids, enzymes, micronutrients, and trace elements to enter cells.

Which End User Segment is Dominant in the Global Market?

The biopharmaceutical companies led the market under the end user segment generating a revenue of US$ 201.1 Mn in 2022.

The demand for recombinant cell culture supplements from biopharmaceutical companies is rising as a result of the expanding use of cell cultures in pharmaceutical research for drug test, ecotoxicology, biological products, gene therapy, and regenerative medicine.

Competitive Landscape

Key players are concentrating on partnerships and acquisitions with suppliers and regional players to increase their market share. This approach is being used by manufacturers to increase their market share. Additionally, producers are concentrating on R&D initiatives as well as the use of recombinant cell culture supplements in many therapeutic and scientific fields.

For instance:

  • In March 2021, Thermo Fisher Scientific released Gibco Human Plasma-like Medium (HPLM). The purpose of this cell culture medium is to provide researchers with a more accurate picture of how cells develop inside the human body.
  • In January 2022, Cytiva (Danaher Corporation) began working along with Nucleus Biologics in order to provide custom products related to culture media for gene and cell therapy.

Similarly, recent developments related to companies providing recombinant cell culture supplements have been tracked by the team at Persistence Market Research, which are available in the full report.

Recombinant Cell Culture Supplements Industry Report Scope

Attribute

Details

Forecast Period

2023-2033

Historical Data Available for

2014-2022

Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • U.K.
  • Germany
  • Italy
  • Russia
  • Spain
  • France
  • BENELUX
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Japan
  • China
  • South Korea
  • India
  • Indonesia
  • Malaysia
  • Thailand
  • Australia
  • New Zealand
  • Turkey
  • GCC Countries
  • Northern Africa
  • South Africa

Key Market Segments Covered

  • Product
  • application
  • source
  • end user
  • Region

Key Companies Profiled

  • Merck, KGaA
  • Thermo Fisher Scientific
  • Lonza Group AG
  • F. Hoffmann-La Roche
  • Abcam PLC.
  • Hi-Media Laboratories
  • Becton, Dickinson and Company
  • STEMCELL Technologies Inc.
  • Fujifilm Corporation
  • InVitria
  • Biocon
  • Cell Sciences, Inc.

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Segments of Recombinant Cell Culture Supplements Industry Research

By Product:

  • Recombinant Growth Factors
    • Transforming Growth Factor
    • Epidermal Growth Factor
    • Platelet-Derived Growth Factors
    • Fibroblast Growth Factor
    • Vascular Endothelial Growth Factors (VEGFs)
    • Interleukins
    • Recombinant Stem Cell Factor
    • Other Growth Factors
  • Recombinant Insulin
  • Recombinant Albumin
  • Recombinant Transferrin
  • Recombinant Trypsin
  • Recombinant Aprotinin
  • Recombinant Lysozyme
  • Others

By Application:

  • Stem Cell Therapy
  • Gene Therapy
  • Bioprocess Application
  • Vaccine Development
  • Others

By Source:

  • Animals
  • Microorganisms
  • Human

By End User:

  • Academic and Research Institutes
  • Biopharmaceutical Companies
  • Cancer Research Centers
  • Contract Research Centers (CROs)

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Merck KGaA
  • Lonza Group AG
  • F. Hoffmann-La Roche
  • Abcam PLC.
  • Hi-Media Laboratories
  • Becton, Dickinson and Company
  • STEMCELL Technologies Inc.
  • Fujifilm Corporation
  • InVitria
  • Biocon
  • Cell Sciences, Inc.

- Frequently Asked Questions -

The global recombinant cell culture supplements market stands at US$ 495.5 Mn in 2022.

Sales of recombinant cell culture supplements are set to witness high growth at a CAGR of 6.0% and reach US$ 947.7 Mn by 2033.

Demand for recombinant cell culture supplements increased at 5.8% CAGR from 2014 to 2022.

North America account for the most demand for recombinant cell culture supplements, currently holding 37.4% of global market share.

The U.S. accounts for the largest share of the North American market, contributing revenue of around US$ 172.4 Mn in 2022

Thermo Fisher Scientific, Merck KGaA and Fujifilm Corporation are the top three manufacturers of recombinant cell culture supplements.

China held a share of 50% in the East Asia market in 2022, while Japan is estimated to grow at a CAGR of 5.8%.

Recombinant cell culture supplements market in Europe is estimated to grow at CAGR of 6.4% share of the global market in 2022.

The increasing research in oncology and stem cell therapy, the demand for novel introduction of therapeutics and biopharmaceuticals, and growing incidence of cancer are some of the key trends in this market.

Germany held 27.2% share of the European market in 2022.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate